欧洲呼吸学会/美国胸科学会重度哮喘管理指南
该指南由欧洲呼吸学会与美国胸科学会联合工作组制定,采用GRADE方法综合证据,针对六个临床问题提出推荐,包括抗IL-5/IL-5Rα、血嗜酸性粒细胞切点、抗IgE治疗识别、噻托溴铵、大环内酯类和抗IL-4/13的应用。
要点
- 建议对重度未控制成人嗜酸性哮喘使用抗IL-5/IL-5Rα治疗。
- 建议以血嗜酸性粒细胞≥150/μL指导成人抗IL-5启动。
- 建议特定嗜酸性粒细胞和FeNO切点识别抗IgE应答人群。
核心结论
- 工作组针对重度哮喘管理提出六条推荐,涉及生物制剂、噻托溴铵和大环内酯类治疗。
研究设计与样本
- 欧洲呼吸学会/美国胸科学会工作组采用GRADE方法综合证据并制定推荐。
主要发现
- 建议对重度未控制成人嗜酸性哮喘使用抗IL-5和抗IL-5受体α治疗。
- 建议以血嗜酸性粒细胞≥150/μL作为成人重度哮喘启动抗IL-5的切点。
- 建议考虑嗜酸性粒细胞≥260/μL和呼出气一氧化氮≥19.5 ppb识别抗IgE治疗最可能应答的青少年或成人。
- 建议对GINA 4-5级或NAEPP 5级治疗后仍重度未控制的青少年和成人使用吸入噻托溴铵。
- 建议对GINA 5级或NAEPP 5级治疗后持续症状或未控制患者试用长期大环内酯治疗以减少急性加重,不论哮喘表型。
关键数值与推荐
- 抗IL-5启动血嗜酸性粒细胞切点≥150/μL。
- 抗IgE应答识别切点:嗜酸性粒细胞≥260/μL和FeNO≥19.5 ppb。
- 吸入噻托溴铵推荐用于GINA 4-5级或NAEPP 5级治疗后仍重度未控制的青少年和成人。
- 长期大环内酯推荐用于GINA 5级或NAEPP 5级治疗后持续症状或未控制患者,不论表型。
- 抗IL-4/13推荐用于重度嗜酸性哮喘成人及重度激素依赖哮喘成人,不论血嗜酸性粒细胞水平。
临床怎么用
- 临床可依据血嗜酸性粒细胞≥150/μL筛选成人重度哮喘患者启动抗IL-5治疗。
- 对抗IgE治疗应答可能更大的青少年或成人,可参考嗜酸性粒细胞≥260/μL和FeNO≥19.5 ppb。
- 对GINA 4-5级或NAEPP 5级治疗后仍未控制者,可考虑吸入噻托溴铵或试用长期大环内酯。
- 重度嗜酸性或激素依赖哮喘成人可考虑抗IL-4/13治疗,后者不论血嗜酸性粒细胞水平。
局限性
- 推荐应随新证据出现而重新评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This document provides clinical recommendations for the management of severe asthma. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the European Respiratory Society/American Thoracic Society Task Force's questions. The evidence was appraised using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of asthma experts, who made specific recommendations on six specific questions. After considering the balance of desirable and undesirable consequences, quality of evidence, feasibility, and acceptability of various interventions, the Task Force made the following recommendations: 1) suggest using anti-interleukin (IL)-5 and anti-IL-5 receptor α for severe uncontrolled adult eosinophilic asthma phenotypes; 2) suggest using a blood eosinophil cut-point ≥150 μL-1 to guide anti-IL-5 initiation in adult patients with severe asthma; 3) suggest considering specific eosinophil (≥260 μL-1) and exhaled nitric oxide fraction (≥19.5 ppb) cut-offs to identify adolescents or adults with the greatest likelihood of response to anti-IgE therapy; 4) suggest using inhaled tiotropium for adolescents and adults with severe uncontrolled asthma despite Global Initiative for Asthma (GINA) step 4-5 or National Asthma Education and Prevention Program (NAEPP) step 5 therapies; 5) suggest a trial of chronic macrolide therapy to reduce asthma exacerbations in persistently symptomatic or uncontrolled patients on GINA step 5 or NAEPP step 5 therapies, irrespective of asthma phenotype; and 6) suggest using anti-IL-4/13 for adult patients with severe eosinophilic asthma and for those with severe corticosteroid-dependent asthma regardless of blood eosinophil levels. These recommendations should be reconsidered as new evidence becomes available.
引用
- Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020. PMID: 31558662. doi:10.1183/13993003.00588-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。